These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 35524896)

  • 1. Icon arrays reduce concern over COVID-19 vaccine side effects: a randomized control study.
    Fansher M; Adkins TJ; Lalwani P; Boduroglu A; Carlson M; Quirk M; Lewis RL; Shah P; Zhang H; Jonides J
    Cogn Res Princ Implic; 2022 May; 7(1):38. PubMed ID: 35524896
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effect of framing and communicating COVID-19 vaccine side-effect risks on vaccine intentions for adults in the UK and the USA: A structured summary of a study protocol for a randomized controlled trial.
    Sudharsanan N; Favaretti C; Hachaturyan V; Bärnighausen T; Vandormael A
    Trials; 2021 Sep; 22(1):592. PubMed ID: 34488843
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Changes in general and COVID-19 vaccine hesitancy among U.S. adults from 2021 to 2022.
    Nguyen KH; Chung EL; McChesney C; Vasudevan L; Allen JD; Bednarczyk RA
    Ann Med; 2024 Dec; 56(1):2357230. PubMed ID: 38813804
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of the suspension of the J&J COVID-19 vaccine on vaccine hesitancy in the United States.
    Hsieh YL; Rak S; SteelFisher GK; Bauhoff S
    Vaccine; 2022 Jan; 40(3):424-427. PubMed ID: 34903374
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tolerance for three commonly administered COVID-19 vaccines by healthcare professionals.
    Melanson SEF; Zhao Z; Kumanovics A; Love T; Meng QH; Wu AHB; Apple F; Ondracek CR; Schulz KM; Wiencek JR; Koch D; Christenson R; Zhang YV
    Front Public Health; 2022; 10():975781. PubMed ID: 36238255
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of side-effect risk framing strategies on COVID-19 vaccine intentions: a randomized controlled trial.
    Sudharsanan N; Favaretti C; Hachaturyan V; Bärnighausen T; Vandormael A
    Elife; 2022 Aug; 11():. PubMed ID: 35971757
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Use of the Janssen (Johnson & Johnson) COVID-19 Vaccine: Updated Interim Recommendations from the Advisory Committee on Immunization Practices - United States, December 2021.
    Oliver SE; Wallace M; See I; Mbaeyi S; Godfrey M; Hadler SC; Jatlaoui TC; Twentyman E; Hughes MM; Rao AK; Fiore A; Su JR; Broder KR; Shimabukuro T; Lale A; Shay DK; Markowitz LE; Wharton M; Bell BP; Brooks O; McNally V; Lee GM; Talbot HK; Daley MF
    MMWR Morb Mortal Wkly Rep; 2022 Jan; 71(3):90-95. PubMed ID: 35051137
    [TBL] [Abstract][Full Text] [Related]  

  • 8. COVID-19 vaccine hesitancy after side effects to the first vaccine: what are our options?
    QJM; 2022 May; 115(5):267. PubMed ID: 35535603
    [No Abstract]   [Full Text] [Related]  

  • 9. COVID-19 vaccine hesitancy in adults with multiple sclerosis in the United States: A follow up survey during the initial vaccine rollout in 2021.
    Ehde DM; Roberts MK; Humbert AT; Herring TE; Alschuler KN
    Mult Scler Relat Disord; 2021 Sep; 54():103163. PubMed ID: 34325399
    [TBL] [Abstract][Full Text] [Related]  

  • 10. From trial to practice: incidence and severity of COVID-19 vaccine side effects in a medically at-risk and vaccine-hesitant community.
    Joyce MC; Mountjoy NJ; Johnson JA; Newman JT; Bandy DL; Atalla NA; Singh A; McElroy D
    BMC Public Health; 2022 Dec; 22(1):2351. PubMed ID: 36517842
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The safety profile of COVID-19 vaccinations in the United States.
    Singh A; Khillan R; Mishra Y; Khurana S
    Am J Infect Control; 2022 Jan; 50(1):15-19. PubMed ID: 34699960
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vaccine hesitancy, state bias, and Covid-19: Evidence from a survey experiment using Phase-3 results announcement by BioNTech and Pfizer.
    Kobayashi Y; Howell C; Heinrich T
    Soc Sci Med; 2021 Aug; 282():114115. PubMed ID: 34157613
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Exploring the adverse events of Oxford-AstraZeneca, Pfizer-BioNTech, Moderna, and Johnson and Johnson COVID-19 vaccination on Guillain-Barré Syndrome.
    Meo SA; Shaikh N; Abukhalaf FA; Meo AS
    Sci Rep; 2024 Aug; 14(1):18767. PubMed ID: 39138276
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A deep learning predictive model for public health concerns and hesitancy toward the COVID-19 vaccines.
    Farghaly HM; Gomaa MM; Elgeldawi E; Askr H; Elshaier YAMM; Ella HA; Darwish A; Hassanien AE
    Sci Rep; 2023 Jun; 13(1):9171. PubMed ID: 37280253
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Artificial Intelligence-Enabled Social Media Analysis for Pharmacovigilance of COVID-19 Vaccinations in the United Kingdom: Observational Study.
    Hussain Z; Sheikh Z; Tahir A; Dashtipour K; Gogate M; Sheikh A; Hussain A
    JMIR Public Health Surveill; 2022 May; 8(5):e32543. PubMed ID: 35144240
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Parental vaccine hesitancy and concerns regarding the COVID-19 virus.
    Salazar TL; Pollard DL; Pina-Thomas DM; Benton MJ
    J Pediatr Nurs; 2022; 65():10-15. PubMed ID: 35367855
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Factors and reasons associated with low COVID-19 vaccine uptake among highly hesitant communities in the US.
    Khairat S; Zou B; Adler-Milstein J
    Am J Infect Control; 2022 Mar; 50(3):262-267. PubMed ID: 34995722
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Side effects after COVID-19 vaccinations among residents of Poland.
    Andrzejczak-Grządko S; Czudy Z; Donderska M
    Eur Rev Med Pharmacol Sci; 2021 Jun; 25(12):4418-4421. PubMed ID: 34227078
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Incidence of multiple sclerosis relapses and pseudo-relapses following COVID-19 vaccination.
    Labani A; Chou S; Kaviani K; Ropero B; Russman K; Becker D
    Mult Scler Relat Disord; 2023 Sep; 77():104865. PubMed ID: 37418929
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reported cases of multisystem inflammatory syndrome in children aged 12-20 years in the USA who received a COVID-19 vaccine, December, 2020, through August, 2021: a surveillance investigation.
    Yousaf AR; Cortese MM; Taylor AW; Broder KR; Oster ME; Wong JM; Guh AY; McCormick DW; Kamidani S; Schlaudecker EP; Edwards KM; Creech CB; Staat MA; Belay ED; Marquez P; Su JR; Salzman MB; Thompson D; Campbell AP;
    Lancet Child Adolesc Health; 2022 May; 6(5):303-312. PubMed ID: 35216660
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.